Brain metastases (BM) are a significant cause of morbidity and mortality, particularly in patients with metastatic breast cancer with HER2+ and TNBC subtypes where the incidence rates are as high as 31% and 32%, respectively, compared to 15% in ER+ breast cancer [82]. This evidence concerns the gene ERBB2 and breast carcinoma.